Phanes Therapeutics Set to Showcase Innovative Cancer Treatments at AACR 2026

Phanes Therapeutics, Inc., a pioneering biotech firm specializing in oncology, is gearing up to present some groundbreaking findings at the upcoming American Association for Cancer Research (AACR) meeting, scheduled from April 17-22, 2026, in San Diego, California. The company will unveil three clinical posters focusing on the efficacy and safety of spevatamig (PT886), a first-in-class bispecific antibody that targets CLDN18.2 and CD47. This promising candidate is currently undergoing a Phase 2 clinical trial, and it showcases Phanes' commitment to advancing cancer treatment through innovative drug discovery.

Key Highlights of the Posters

The presentations will take place during the Phase II and Phase III Clinical Trials Session. Below is a summary of what attendees can expect:

1. Poster Title: Pharmacokinetics of spevatamig in Patients with Advanced Gastrointestinal Cancers as Monotherapy or Combination Therapy
Date/Time: April 20, 2026, between 2:00 - 5:00 PM PST
Location: Poster Section 52, Poster Board Number 8
Presenter: Anwaar Saeed, MD, from the University of Pittsburgh Medical Center
This poster will delve into the pharmacokinetic properties of spevatamig, detailing how the bispecific antibody behaves in patients suffering from advanced gastrointestinal malignancies, whether used alone or in combination with other treatments.

2. Poster Title: Reducing Nausea and Vomiting while Maintaining Efficacy with spevatamig
Date/Time: April 20, 2026, 2:00 - 5:00 PM PST
Location: Poster Section 52, Poster Board Number 6
Presenter: Michael Overman, MD, from the University of Texas MD Anderson Cancer Center
This presentation is expected to highlight how spevatamig could minimize common side effects such as nausea and vomiting in patients, while ensuring the treatment remains effective against cancer.

3. Poster Title: Resolved Hematological Toxicities Associated with Anti-CD47 Agents Using a Bispecific Design
Date/Time: April 20, 2026, 2:00 - 5:00 PM PST
Location: Poster Section 52, Poster Board Number 7
Presenter: Harshabad Singh, MD, from Mass General Brigham
This session will present findings from a clinical proof-of-concept study showcasing how the bispecific design of spevatamig effectively mitigates hematological toxicities typically seen with anti-CD47 therapeutic agents.

About Spevatamig

Spevatamig is noteworthy for being a first-in-class native IgG-like bispecific antibody specifically targeting claudin 18.2 and CD47. The FDA recognized its potential by granting orphan drug designation for treating pancreatic cancer in 2022, and it subsequently received Fast Track designation for patients with metastatic claudin 18.2-positive pancreatic adenocarcinoma in 2024.

In a strategic move to bolster its clinical research, Phanes formed a collaboration with Merck to investigate the effects of spevatamig in combination with Merck's anti-PD-1 therapy, pembrolizumab. The ongoing Phase 1/2 clinical trial (NCT05482893) is evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of spevatamig across various advanced cancer types including gastric and pancreatic cancers.

Phanes Therapeutics' Vision

Headquartered in San Diego, Phanes Therapeutics is a clinical-stage immuno-oncology company dedicated to developing a unique portfolio of differentiated antibody therapeutics aimed at treating solid tumors. The company's leading asset, spevatamig, has demonstrated promising Phase 2 results for metastatic pancreatic ductal adenocarcinoma, while ongoing projects involve other bispecific antibodies targeting cancers like small cell lung cancer.

As representatives from Phanes prepare to share these vital findings with the oncology community, the anticipation builds around the revolutionary potential that spevatamig may offer in cancer treatment. This engagement at AACR 2026 could mark a significant milestone in the company's journey toward improving outcomes for patients facing formidable cancer diagnoses.